CDK2 transcriptional repression is an essential effector in p53-dependent cellular senescence-implications for
Hasan Zalzali1, Bilal Nasr2, Mohamad Harajly2
1Department of Pediatric and Adolescent Medicine, American University of Beirut, Beirut, Lebanon. hz13@aub.edu.lb rs88@aub.edu.lb.
Unlabelled:
Cellular senescence, a form of cell-cycle arrest, is a tumor-suppressor mechanism triggered by multiple tumor-promoting insults, including oncogenic stress and DNA damage. The role of cyclin-dependent kinase 2 (CDK2) regulation has been evaluated in models of replicative senescence, but little is known regarding its role in other senescence settings. Using in vitro and in vivo models of DNA damage-and oncogene-induced cellular senescence, it was determined that activation of the tumor-suppressor protein p53 (TP53) resulted in repression of the CDK2 transcript that was dependent on intact RB. Ectopic CDK2 expression was sufficient to bypass p53-dependent senescence, and CDK2-specific inhibition, either pharmacologically (CVT313) or by use of a dominant-negative CDK2, was sufficient to induce early senescence. Pharmacologic inhibition of CDK2 in an in vivo model of pineal tumor decreased proliferation and promoted early senescence, and it also decreased tumor penetrance and prolonged time to tumor formation in animals lacking p53. In conclusion, for both oncogene- and DNA damage-induced cellular senescence, CDK2 transcript and protein are decreased in a p53- and RB-dependent manner, and this repression is necessary for cell-cycle exit during senescence.
Implications:
These data show that CDK2 inhibition may be useful for cancer prevention in premalignant hyperproliferative lesions, as well as established tumors.
Insights
Cyclin-dependent kinase 2 (CDK2) repression is essential for p53- and RB-dependent cellular senescence induction. CDK2 inhibition shows promise for cancer prevention and treatment by promoting senescence in tumors.
Area of Science:
- Cellular senescence
- Oncogenesis
- Tumor suppression
Background:
- Cellular senescence is a tumor-suppressor mechanism triggered by oncogenic stress and DNA damage, leading to cell-cycle arrest.
- The role of cyclin-dependent kinase 2 (CDK2) in senescence, particularly in DNA damage- and oncogene-induced settings, is not well understood.
Purpose of the Study:
- To investigate the role of CDK2 regulation in DNA damage- and oncogene-induced cellular senescence.
- To determine if CDK2 inhibition can be a therapeutic strategy for cancer prevention and treatment.
Main Methods:
- Utilized in vitro and in vivo models of DNA damage- and oncogene-induced cellular senescence.
- Assessed the impact of p53 (TP53) activation, RB integrity, and ectopic CDK2 expression on senescence.
- Employed pharmacological inhibition (CVT313) and dominant-negative approaches to inhibit CDK2.
- Evaluated CDK2 inhibition in an in vivo model of pineal tumors.
Main Results:
- p53 activation led to repression of CDK2, dependent on intact RB.
- Ectopic CDK2 expression bypassed p53-dependent senescence.
- CDK2 inhibition induced early senescence and reduced proliferation.
- In vivo, pharmacologic CDK2 inhibition decreased tumor penetrance and prolonged tumor formation time, even in p53-deficient animals.
Conclusions:
- CDK2 transcript and protein are decreased in a p53- and RB-dependent manner during oncogene- and DNA damage-induced senescence.
- Repression of CDK2 is necessary for cell-cycle exit in these senescence pathways.
- CDK2 inhibition presents a potential therapeutic strategy for cancer prevention and treatment of established tumors.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle


